Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708307 | 0.89 | PTGS1 (0.32) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL26306147 | 0.89 | APP (0.33) | APP | |
| SCHEMBL23268443 | 0.86 | APP (0.31) | APP | |
| SCHEMBL11242639 | 0.81 | APP (0.39) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL26306079 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL3489362 | 0.77 | — | — | |
| SCHEMBL26306163 | 0.76 | APP (0.32) | APP | |
| SCHEMBL23268493 | 0.76 | — | — | |
| SCHEMBL23268444 | 0.73 | APP (0.31) | APP | |
| SCHEMBL23541956 | 0.73 | APP (0.44) | APPPTGS1PDE4ALMNASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040108207-A1 | Injection and separation system and method employing transient isotachophoretic stacking | ACLARA BIOSCIENCES, INC. | 2004-06-10 | — | — | US | claimed |
| US-6309815-B1 | EXPANDING SEMEN VIABILITY; WASH ANIMAL, RECOVER SEMEN FROM ANIMAL, EXPOSE TO STORAGE BUFFER, STORE SEMEN, ACTIVATE SEMEN | UNIVERSITY OF KANSAS MEDICAL CENTER | 2001-10-30 | — | — | US | claimed |
| US-4898652-A | Polyoxalkylated polyhydroxy compounds as additives in zinc alloy electrolytes | OMI INTERNATIONAL CORPORATION (US) | 1990-02-06 | — | — | US | claimed |
| EP-4737504-A2 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4276090-B1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4321504-B1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20240342088-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-10-17 | — | — | US | disclosed |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| EP-4321503-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED THEREBY, PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME, PREPARATION THEREOF, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321504-A1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| EP-0654095-A1 | ELECTROPHORESIS OF NUCLEIC ACID FRAGMENTS | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1995-05-24 | — | — | EP | disclosed |
| US-5391380-A | Thromboplastin extract, reagent, and preparation thereof | HELENA LABORATORIES, CORP. (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0634010-A1 | ELECTROPHORESIS OF NUCLEIC ACID FRAGMENTS | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1994003643-A1 | ELECTROPHORESIS OF NUCLEIC ACID FRAGMENTS | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993020434-A1 | ELECTROPHORESIS OF NUCLEIC ACID FRAGMENTS | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0540585-A1 | COMPETITIVE PCR FOR QUANTITATION OF DNA. | CEMU BIOTEKNIK AB (SE) | 1993-05-12 | — | — | EP | disclosed |
| EP-0524803-A2 | Thromboplastin extract, reagent, and preparation thereof | HELENA LABORATORIES CORPORATION (US) | 1993-01-27 | — | — | EP | disclosed |
| WO-1992001812-A1 | COMPETITIVE PCR FOR QUANTITATION OF DNA | CEMU BIOTEKNIK AB (SE) | 1992-02-06 | — | — | WO | disclosed |
| US-4898652-A | Polyoxalkylated polyhydroxy compounds as additives in zinc alloy electrolytes | OMI INTERNATIONAL CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180951-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, PHOSPHO1, LDLR | APP 3657/4885PTGS1 1463/4885PDE4A 4048/4885 |
| US-20240342088-A1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | NPC1, SLC27A1, SLC7A1 | APP 2029/4885PTGS1 698/4885PDE4A 3533/4885 |
| US-20240197633-A1 | PEGYLATED LIPID, LIPOSOME MODIFIED BY THE LIPID, PHARMACEUTICAL COMPOSITION CONTAINING THE LIPOSOME, FORMULATION AND APPLICATION THEREOF | LIPG, LDLR, LIPA | APP 3606/4885PTGS1 2520/4885PDE4A 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.